Propanc Completes Successful Roadshow in New York City

Up-listing to National Exchange Keenly Discussed with Leading Financial Institutions

MELBOURNE, Australia, May 11, 2016 /PRNewswire/ -- Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that the Company's CEO, Mr. James Nathanielsz, enjoyed a productive week conducting meetings with leading financial institutions and retail brokers in the greater New York area.

Mr Stan Wunderlich, CEO, Consulting for Strategic Growth 1 (left), Mr James Nathanielsz, CEO, Propanc Health Group Corp (center) and  Investment Banker (right), tour the New York Stock Exchange on Wednesday, May 4th.

A number of luncheons were conducted so that they would hear and learn directly about the status of Propanc's R&D activities, with a particular focus on their lead product, PRP, as well as their vision for the future.  With the recent successful completion of the MHRA meeting last month, the pathway is now defined to rapidly progress PRP into first-in-man studies.

"Given the status of development of our lead product, PRP, we are in the process of transforming our Company into a clinical stage biopharmaceutical company," said Mr. Nathanielsz.  "Unlocking value as a result of our recent progress is a key priority.  Ideas which come to mind include up-listing to a national exchange with the right support from one or more leading financial institutions, or seeking strategic partners interested in the co-development of PRP.  Either one or both of these key activities, as well as continuing to progress PRP to patient trials, will enable us to progress towards becoming a leading oncology player, which is our mission."

A number of productive Q&A sessions were also conducted, where Mr. Nathanielsz was delighted with both the turnout and interest to learn more about the Company.

"As a result of these past few days, I am motivated to re-energize myself back in Melbourne and then return as quickly as possible to attend a few conferences in and around the New York City area to meet with additional interested parties.  We intend to present our most recent scientific data showing PRP's effectiveness against cancer stem cells, and how we plan to deliver a new approach to the treatment and prevention of metastatic cancer.  I very much look forward to my next trip back to the United States."

The Company aims to fast track the development of proenzyme related oncology products into clinical trials initially for pancreatic and ovarian cancers, followed by colorectal cancer. According to Global Analyst Reports, the combined world market for pancreatic, ovarian and colorectal cancers are expected to reach over $12 billion by 2020.

About Propanc:   
Propanc is developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes.

In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening.  For more information, visit:

Forward-looking Statements:  
Certain of the matters discussed in this announcement involve risks and uncertainties  including, without limitation, those regarding the Company's ability to establish and maintain the proprietary nature of its  technology through the patent process, its ability to license from others patents and patent applications, if necessary, to develop certain products, its ability to implement its long range business plan for various applications of its technology, and its ability to enter into agreements with any necessary marketing and/or distribution partners for purposes of commercialization. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position.  See Propanc's most recent Quarterly Report on Form 10-Q and related 8K filings.

Life-changing Biotech

Photo -  
Logo -

To view the original version on PR Newswire, visit:

SOURCE Propanc Health Group Corporation

Sign up for email alerts

Be the first to receive breaking news

Sign up today